Difficult-to-control asthma may improve after diagnosis, inhaler technique, adherence, exposures, comorbidities, or treatment are corrected. Severe asthma remains uncontrolled despite optimized high-intensity treatment or requires that treatment to stay controlled.
Bring prior spirometry or lung tests, emergency and hospitalization records, steroid-burst dates, medication and inhaler list, refill history when available, allergy tests, blood work, imaging, and notes from primary care, allergy, or pulmonary clinicians.
No all-site testing promise is made. The clinician reviews existing results and confirms which tests are needed, where they can be completed, and whether pulmonary or allergy referral is appropriate.
The choice considers the exact label, age, allergic or eosinophilic features, exacerbations, steroid dependence, nasal polyps or other conditions, dosing, route, safety, access, and patient preferences.
The U.S. severe-asthma indication is not limited to a named eosinophil threshold. The clinician still reviews phenotype, prior treatment, overall clinical fit, and payer requirements.
Do not stop inhaled or systemic corticosteroids abruptly. Biologics are add-on maintenance treatment, and any reduction must be gradual and supervised.
Response timing varies by product and patient. The prescriber defines a reasonable trial and tracks exacerbations, symptoms, lung function, steroid exposure, safety, and daily function rather than promising an immediate result.
Do not expect same-day administration. The workup, prescription, authorization, medication delivery, eligible site, and product-specific safety plan generally come first.